Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Verrica Pharmaceuticals Inc.VRCA · Entity 6823 | CHIEF LEGAL OFFICER | March 14, 2025 | March 18, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Verrica Pharmaceuticals Inc.
Report date March 14, 2025 · Filed March 18, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 176,458 |
Reported balance
After 2025-03-17 transaction · row 1
1 source rowRow 1 · 2025-03-17 · Sale · Disposed 4,315 · Balance 176,458 F1: Represents the number of shares required to be sold to cover the statutory tax withholding obligations in connection with the settlement of the restricted stock units. This sale was mandated by the Issuer's election under its 2018 equity incentive plan to require the satisfaction of minimum statutory tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary sale by the Reporting Person. F2: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.6378 to $0.6605 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. |
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.89 · Expires 2035-03-14 | Direct | 250,000 |
Reported balance
After 2025-03-14 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2025-03-14 · Grant · Acquired 250,000 · Balance 250,000 F3: 50% of the total shares subject to the option shall vest on each of March 14, 2026 and March 14, 2027, subject to the Reporting Person's continuous service through such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents the number of shares required to be sold to cover the statutory tax withholding obligations in connection with the settlement of the restricted stock units. This sale was mandated by the Issuer's election under its 2018 equity incentive plan to require the satisfaction of minimum statutory tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary sale by the Reporting Person.
F2: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.6378 to $0.6605 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
F3: 50% of the total shares subject to the option shall vest on each of March 14, 2026 and March 14, 2027, subject to the Reporting Person's continuous service through such vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 17, 2025 Filed Mar 18, 2025 18:45 UTC | Verrica Pharmaceuticals Inc. VRCA · Entity 6823 | SaleCommon Stock | 4,315 | $0.65 | $2,804.75 |
DisclosureSEC source: 0001415889-25-008505 · form4-03182025_060301.xml · nonDerivative · entry 1 Hayes Christopher G. · CIK 0001805359 · CHIEF LEGAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 176,458 F1 · kind: Represents the number of shares required to be sold to cover the statutory tax withholding obligations in connection with the settlement of the restricted stock units. This sale was mandated by the Issuer's election under its 2018 equity incentive plan to require the satisfaction of minimum statutory tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary sale by the Reporting Person. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.6378 to $0.6605 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| March 14, 2025 Filed Mar 18, 2025 18:45 UTC | Verrica Pharmaceuticals Inc. VRCA · Entity 6823 | GrantEmployee Stock Option (right to buy) · Derivative | 250,000 | $0.00 Strike: $0.89 | $0.00 |
DisclosureSEC source: 0001415889-25-008505 · form4-03182025_060301.xml · derivative · entry 2 Hayes Christopher G. · CIK 0001805359 · CHIEF LEGAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 250,000 Underlying: Common Stock · 250,000 shares Expires 2035-03-14 F3 · derivative.exercise_date: 50% of the total shares subject to the option shall vest on each of March 14, 2026 and March 14, 2027, subject to the Reporting Person's continuous service through such vesting date. Read SEC document |
| October 09, 2024 Filed Oct 11, 2024 16:15 UTC | Verrica Pharmaceuticals Inc. VRCA · Entity 6823 | GrantEmployee Stock Option (right to buy) · Derivative | 50,000 | $0.00 Strike: $1.28 | $0.00 |
DisclosureSEC source: 0001415889-24-025026 · form4-10112024_041004.xml · derivative · entry 1 Hayes Christopher G. · CIK 0001805359 · CHIEF LEGAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2034-10-09 F1 · derivative.exercise_date: 50% of the total shares subject to the option shall vest on each of April 9, 2025 and October 9, 2025, subject to the Reporting Person's continuous service through such vesting date. Read SEC document |
| August 27, 2024 Filed Aug 28, 2024 16:15 UTC | Verrica Pharmaceuticals Inc. VRCA · Entity 6823 | SaleCommon Stock | 9,530 | $2.46 | $23,443.80 |
DisclosureSEC source: 0001415889-24-022427 · form4-08282024_040809.xml · nonDerivative · entry 2 Hayes Christopher G. · CIK 0001805359 · CHIEF LEGAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 105,773 F1 · kind: Represents the number of shares required to be sold to cover the statutory tax withholding obligations in connection with the settlement of the restricted stock units. This sale was mandated by the Issuer's election under its 2018 equity incentive plan to require the satisfaction of minimum statutory tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary sale by the Reporting Person. F3 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.40 to $2.53 inclusive. Read SEC document |
| August 26, 2024 Filed Aug 28, 2024 16:15 UTC | Verrica Pharmaceuticals Inc. VRCA · Entity 6823 | SaleCommon Stock | 26,183 | $2.66 | $69,646.78 |
DisclosureSEC source: 0001415889-24-022427 · form4-08282024_040809.xml · nonDerivative · entry 1 Hayes Christopher G. · CIK 0001805359 · CHIEF LEGAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 115,303 F1 · kind: Represents the number of shares required to be sold to cover the statutory tax withholding obligations in connection with the settlement of the restricted stock units. This sale was mandated by the Issuer's election under its 2018 equity incentive plan to require the satisfaction of minimum statutory tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary sale by the Reporting Person. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.53 to $2.83 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) and (3). Read SEC document |
| July 23, 2024 Filed Jul 23, 2024 18:10 UTC | Verrica Pharmaceuticals Inc. VRCA · Entity 6823 | SaleCommon Stock | 91 | $6.98 | $635.18 |
DisclosureSEC source: 0001415889-24-019970 · form4-07232024_100729.xml · nonDerivative · entry 2 Hayes Christopher G. · CIK 0001805359 · CHIEF LEGAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 141,486 F1 · shares: Represents the number of shares required to be sold to cover the statutory tax withholding obligations in connection with the settlement of the restricted stock units. This sale was mandated by the Issuer's election under its 2018 equity incentive plan to require the satisfaction of minimum statutory tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary sale by the Reporting Person. Read SEC document |
| July 22, 2024 Filed Jul 23, 2024 18:10 UTC | Verrica Pharmaceuticals Inc. VRCA · Entity 6823 | SaleCommon Stock | 21,649 | $7.06 | $152,841.94 |
DisclosureSEC source: 0001415889-24-019970 · form4-07232024_100729.xml · nonDerivative · entry 1 Hayes Christopher G. · CIK 0001805359 · CHIEF LEGAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 141,577 F1 · shares: Represents the number of shares required to be sold to cover the statutory tax withholding obligations in connection with the settlement of the restricted stock units. This sale was mandated by the Issuer's election under its 2018 equity incentive plan to require the satisfaction of minimum statutory tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary sale by the Reporting Person. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.00 to $7.17 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| March 15, 2024 Filed Mar 19, 2024 16:31 UTC | Verrica Pharmaceuticals Inc. VRCA · Entity 6823 | GrantEmployee Stock Option (right to buy) · Derivative | 80,000 | $0.00 Strike: $4.80 | $0.00 |
DisclosureSEC source: 0001415889-24-008543 · form4-03192024_040300.xml · derivative · entry 2 Hayes Christopher G. · CIK 0001805359 · CHIEF LEGAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 80,000 Underlying: Common Stock · 80,000 shares Expires 2034-03-15 F2 · derivative.exercise_date: 25% of the total shares subject to the option shall vest on March 15, 2025 and 1/48th of the total shares subject to the option shall vest monthly thereafter over the remaining three years of the vesting period, subject to the Reporting Person's continuous service through such vesting date. Read SEC document |
| March 15, 2024 Filed Mar 19, 2024 16:31 UTC | Verrica Pharmaceuticals Inc. VRCA · Entity 6823 | GrantCommon Stock | 40,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-008543 · form4-03192024_040300.xml · nonDerivative · entry 1 Hayes Christopher G. · CIK 0001805359 · CHIEF LEGAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 163,226 F1 · shares: Represents a restricted stock unit ("RSU") award. The RSUs shall vest in equal annual installments on March 15, 2025, March 15, 2026, March 15, 2027 and March 15, 2028 subject to the Reporting Person's continuous service through each applicable date. Read SEC document |
| November 15, 2023 Filed Nov 16, 2023 16:32 UTC | Verrica Pharmaceuticals Inc. VRCA · Entity 6823 | SaleCommon Stock | 11,558 | $2.97 | $34,327.26 |
DisclosureSEC source: 0001209191-23-055527 · doc4.xml · nonDerivative · entry 2 Hayes Christopher G. · CIK 0001805359 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 123,226 F1 · kind: Shares sold to satisfy withholding tax obligations upon the delivery of shares of common stock for RSUs that vested on August 24, 2023. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.95 to $3.00 inclusive. Read SEC document |
| November 14, 2023 Filed Nov 16, 2023 16:32 UTC | Verrica Pharmaceuticals Inc. VRCA · Entity 6823 | SaleCommon Stock | 22,141 | $2.93 | $64,873.13 |
DisclosureSEC source: 0001209191-23-055527 · doc4.xml · nonDerivative · entry 1 Hayes Christopher G. · CIK 0001805359 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 134,784 F1 · kind: Shares sold to satisfy withholding tax obligations upon the delivery of shares of common stock for RSUs that vested on August 24, 2023. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.90 to $3.07 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) and (3). Read SEC document |
| August 24, 2023 Filed Aug 28, 2023 16:39 UTC | Verrica Pharmaceuticals Inc. VRCA · Entity 6823 | GrantCommon Stock | 75,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-047521 · doc4.xml · nonDerivative · entry 1 Hayes Christopher G. · CIK 0001805359 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 156,925 F1 · shares: Represents vesting of shares of common stock underlying performance stock units resulting from the achievement of certain non-financial milestones. These shares have not been delivered. Read SEC document |
| August 24, 2023 Filed Feb 6, 2025 16:15 UTC Amendment | Verrica Pharmaceuticals Inc. VRCA · Entity 6823 | GrantCommon Stock | 150,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-003232 · form4a-02062025_040206.xml · nonDerivative · entry 1 Hayes Christopher G. · CIK 0001805359 · CHIEF LEGAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 231,925 F1 · shares: Represents restricted stock unit ("RSU") awards with performance based vesting, which were originally granted in March 2023. The RSUs vested 50% upon the first commercial sale of VP-102 on August 24, 2023, and the remaining 50% vested on August 24, 2024, the one year anniversary of the first sale. F2 · shares: The number of RSUs awarded in the initial Form 4 was unintentionally misreported, as only the number of shares that vested on August 24, 2023 were reported as opposed to the full size of the award. This amendment corrects the number RSUs awarded and the number of securities beneficially owned after the reported transaction. F2 · balance_after: The number of RSUs awarded in the initial Form 4 was unintentionally misreported, as only the number of shares that vested on August 24, 2023 were reported as opposed to the full size of the award. This amendment corrects the number RSUs awarded and the number of securities beneficially owned after the reported transaction. Read SEC document |
| July 24, 2023 Filed Jul 25, 2023 16:25 UTC | Verrica Pharmaceuticals Inc. VRCA · Entity 6823 | SaleCommon Stock | 33,789 | $4.83 | $163,200.87 |
DisclosureSEC source: 0001209191-23-043306 · doc4.xml · nonDerivative · entry 2 Hayes Christopher G. · CIK 0001805359 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 81,925 F2 · kind: Shares sold to satisfy withholding tax obligations upon the delivery of shares of common stock for RSUs that vested on July 21, 2023. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.75 to $4.955 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| July 21, 2023 Filed Jul 25, 2023 16:25 UTC | Verrica Pharmaceuticals Inc. VRCA · Entity 6823 | GrantCommon Stock | 100,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-043306 · doc4.xml · nonDerivative · entry 1 Hayes Christopher G. · CIK 0001805359 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 115,714 F1 · shares: Represents restricted stock unit ("RSU") awards with performance based vesting, which were originally granted in 2019 and 2020. The RSUs vested 50% upon receipt of regulatory approval of the Issuer's new drug application for VP-102 for the treatment of molluscum, and the remaining 50% shall vest on July 21, 2024, subject to the Reporting Person's continuous service through each applicable date. Read SEC document |
| March 01, 2023 Filed Mar 3, 2023 16:25 UTC | Verrica Pharmaceuticals Inc. VRCA · Entity 6823 | GrantEmployee Stock Option (right to buy) · Derivative | 135,000 | $0.00 Strike: $7.58 | $0.00 |
DisclosureSEC source: 0001209191-23-015492 · doc4.xml · derivative · entry 1 Hayes Christopher G. · CIK 0001805359 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 135,000 Underlying: Common Stock · 135,000 shares Expires 2033-02-28 F1 · derivative.exercise_date: 25% of the total shares subject to the option shall vest on March 1, 2024 and 1/48th of the total shares subject to the option shall vest monthly thereafter over the remaining three years of the vesting period, subject to the Reporting Person's continuous service through such vesting date. Read SEC document |
| July 11, 2022 Filed Jul 11, 2022 17:24 UTC | Verrica Pharmaceuticals Inc. VRCA · Entity 6823 | PurchaseCommon Stock | 7,500 | $3.40 | $25,500.00 |
DisclosureSEC source: 0001209191-22-041835 · doc4.xml · nonDerivative · entry 1 Hayes Christopher G. · CIK 0001805359 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,714 Read SEC document |
| July 05, 2022 Filed Jul 5, 2022 16:13 UTC | Verrica Pharmaceuticals Inc. VRCA · Entity 6823 | PurchaseCommon Stock | 5,714 | $2.10 | $11,999.40 |
DisclosureSEC source: 0001209191-22-040616 · doc4.xml · nonDerivative · entry 1 Hayes Christopher G. · CIK 0001805359 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,214 Read SEC document |
| February 24, 2022 Filed Feb 25, 2022 16:37 UTC | Verrica Pharmaceuticals Inc. VRCA · Entity 6823 | GrantEmployee Stock Option (right to buy) · Derivative | 75,000 | $0.00 Strike: $8.00 | $0.00 |
DisclosureSEC source: 0001209191-22-013202 · doc4.xml · derivative · entry 1 Hayes Christopher G. · CIK 0001805359 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Stock · 75,000 shares Expires 2032-02-23 F1 · derivative.exercise_date: 25% of the total shares subject to the option shall vest on February 24, 2023 and 1/48th of the total shares subject to the option shall vest monthly thereafter over the remaining three years of the vesting period, subject to the Reporting Person's continuous service through such vesting date. Read SEC document |
| June 04, 2021 Filed Jun 7, 2021 08:42 UTC | Verrica Pharmaceuticals Inc. VRCA · Entity 6823 | PurchaseCommon Stock | 2,500 | $9.79 | $24,475.00 |
DisclosureSEC source: 0001209191-21-038481 · doc4.xml · nonDerivative · entry 1 Hayes Christopher G. · CIK 0001805359 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,500 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $9.782 to $9.803 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Read SEC document |
| March 01, 2021 Filed Mar 3, 2021 17:01 UTC | Verrica Pharmaceuticals Inc. VRCA · Entity 6823 | GrantEmployee Stock Option (Right to Buy) · Derivative | 65,000 | $0.00 Strike: $14.32 | $0.00 |
DisclosureSEC source: 0001209191-21-016972 · doc4.xml · derivative · entry 1 Hayes Christopher G. · CIK 0001805359 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,000 Underlying: Common Stock · 65,000 shares Expires 2031-02-28 F1 · derivative.exercise_date: 25% of the total shares subject to the option shall vest on March 1, 2022 and 1/48th of the total shares subject to the option shall vest monthly thereafter over the remaining three years of the vesting period, subject to the Reporting Person's continuous service through such vesting date. Read SEC document |
| February 27, 2020 Filed Mar 3, 2020 18:19 UTC | Verrica Pharmaceuticals Inc. VRCA · Entity 6823 | GrantEmployee Stock Option (Right to Buy) · Derivative | 55,000 | $0.00 Strike: $11.81 | $0.00 |
DisclosureSEC source: 0001209191-20-015606 · doc4.xml · derivative · entry 1 Hayes Christopher G. · CIK 0001805359 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,000 Underlying: Common Stock · 55,000 shares Expires 2030-02-26 F1 · derivative.exercise_date: 25% of the total shares subject to the option shall vest on February 27, 2021 and 1/48th of the total shares subject to the option shall vest monthly thereafter over the remaining three years of the vesting period, subject to the Reporting Person's continuous service through such vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.